202 related articles for article (PubMed ID: 29866013)
1. Trends of Clinical Trials for Drug Development in Rare Diseases.
Sakate R; Fukagawa A; Takagaki Y; Okura H; Matsuyama A
Curr Clin Pharmacol; 2018; 13(3):199-208. PubMed ID: 29866013
[TBL] [Abstract][Full Text] [Related]
2. Statistical considerations for rare diseases drug development.
Chow SC; Chang YW
J Biopharm Stat; 2019; 29(5):874-886. PubMed ID: 31454299
[TBL] [Abstract][Full Text] [Related]
3. Innovative design and analysis for rare disease drug development.
Chow SC; Huang Z
J Biopharm Stat; 2020 May; 30(3):537-549. PubMed ID: 32065047
[TBL] [Abstract][Full Text] [Related]
4. Patients left behind: Rare dermatologic conditions miss the orphan drug development boom.
Chavez A; Licholai G; Murrell DF
J Am Acad Dermatol; 2019 Oct; 81(4):1025-1026. PubMed ID: 30880063
[No Abstract] [Full Text] [Related]
5. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
6. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network.
Shimizu R; Ogata K; Tamaura A; Kimura E; Ohata M; Takeshita E; Nakamura H; Takeda S; Komaki H
BMC Health Serv Res; 2016 Jul; 16():241. PubMed ID: 27401940
[TBL] [Abstract][Full Text] [Related]
8. Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseases.
Micallef J; Blin O
Therapie; 2020 Apr; 75(2):133-139. PubMed ID: 32156423
[TBL] [Abstract][Full Text] [Related]
9. [Orphanet and the Dutch Steering Committee Orphan Drugs. A European and Dutch databank of information on rare diseases].
Liem SL
Ned Tijdschr Tandheelkd; 2008 Nov; 115(11):621-3. PubMed ID: 19058507
[TBL] [Abstract][Full Text] [Related]
10. [The legal regulation of life cycle of orphan pharmaceuticals].
Gildeyeva GN; Kartavtsova TV
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of clinical trial status discrepancies: A cross-sectional study of 10,492 trials registered on both ClinicalTrials.gov and the European Union Clinical Trials Register.
Fleminger J; Goldacre B
PLoS One; 2018; 13(3):e0193088. PubMed ID: 29513684
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology.
Micallef J; Boutouyrie P; Blin O
Fundam Clin Pharmacol; 2017 Dec; 31(6):685-694. PubMed ID: 28779530
[TBL] [Abstract][Full Text] [Related]
13. Increasing the use of orphan drugs in clinical practice.
Hulton SA; Greener M
Hosp Med; 2004 Jul; 65(7):400-3. PubMed ID: 15287343
[TBL] [Abstract][Full Text] [Related]
14. Improvement of Pediatric Drug Development: Regulatory and Practical Frameworks.
Tsukamoto K; Carroll KA; Onishi T; Matsumaru N; Brasseur D; Nakamura H
Clin Ther; 2016 Mar; 38(3):574-81. PubMed ID: 26869192
[TBL] [Abstract][Full Text] [Related]
15. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
16. Factors distinguishing important identified risks from important potential risks in orphan and nonorphan drugs: An analysis of safety specifications of Japan and European Union risk management plans.
Hirota S; Yamaguchi T
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1231-1238. PubMed ID: 30187590
[TBL] [Abstract][Full Text] [Related]
17. Increasing orphan drug loss in Japan: Trends and R&D strategy for rare diseases.
Enya K; Lim Y; Sengoku S; Kodama K
Drug Discov Today; 2023 Oct; 28(10):103755. PubMed ID: 37648019
[TBL] [Abstract][Full Text] [Related]
18. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Pediatric Drug Approval Lag in Japan.
Ueyama E; Kaneko M; Narukawa M
Ther Innov Regul Sci; 2021 Mar; 55(2):336-345. PubMed ID: 32959206
[TBL] [Abstract][Full Text] [Related]
20. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
Maier WC; Christensen RA; Anderson P
Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
